Developer docs
API playgroundTry for free, no card

Search company profiles

Biocept

Full company profile

uuid0005q6l

Namestring
Biocept
Legal namestring
Biocept Inc.
Websiteurl
biocept.com
Company typeenum
Public
Founded yearint
1993
Descriptiontext

Biocept is a San Diego-based clinical diagnostics company founded in 1993 and publicly traded on NASDAQ under ticker BIOC. The company developed a proprietary circulating tumor cell (CTC) detection platform built on a microfluidic chip-based cell separation technology, which it applies to liquid biopsy testing in oncology. Its lead commercial product is CNSide (also referenced as IN/CNSide), a cerebrospinal fluid (CSF) liquid biopsy assay designed to detect CTCs expressing the neuroendocrine marker synaptophysin in patients with leptomeningeal disease and central nervous system (CNS) cancers — a positioning differentiated from most liquid biopsy peers that focus on blood-based analysis. The assay is being evaluated in the FORESEE clinical trial for clinical validation.

Biocept operates as a clinical laboratory offering laboratory-developed tests (LDTs) to practicing oncologists and neuro-oncologists, generating revenue through test reimbursement rather than a direct-to-consumer or kit-based model. Its customer base is concentrated among neuro-oncology practices and academic medical centers managing patients with CNS metastases or leptomeningeal carcinomatosis. Pricing, payer mix, and reimbursement structure are not publicly disclosed in available sources. The company has raised approximately $48 million cumulatively across equity rounds from 2002 through 2023, with the most recent disclosed raise of $5 million in May 2023.

Operationally, Biocept runs a lean organization of 51-100 employees under a leadership team including CEO Antonino Morales, Chairman Samuel D. Riccitelli, COO Philippe Marchand, CMO Michael Dugan, CSO Lyle Arnold, and General Counsel Darrell Taylor. A material operational concern is that the company's website returned a DNS resolution error as of July 2026, which is consistent with severe financial distress, business interruption, or potential wind-down — a critical diligence flag for any investor or counterparty evaluating the company.

Short descriptiontext

Biocept is a San Diego-based clinical diagnostics company that develops microfluidic circulating tumor cell liquid biopsy assays, primarily serving neuro-oncologists with its CNSide cerebrospinal fluid assay for CNS cancer and leptomeningeal disease monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
liquid biopsy diagnostics, circulating tumor cells, cancer diagnostic assays, microfluidic chip platform, cerebrospinal fluid assay
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Cancer Diagnostics
Social media profiles3 records
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Biocept develops and commercializes cerebrospinal fluid liquid biopsy assays — principally the CNSide/IN-CNSide assay — that detect circulating tumor cells (CTCs) expressing synaptophysin. These microfluidic chip-based assays are used by clinicians to monitor patients with leptomeningeal disease and central nervous system cancers when conventional cytology fails to identify malignant cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Detected CTCs expressing synaptophysin in CSF at seven time points over eight months while conventional cytology remained negative throughout monitoring period
Product overview1 text field

Biocept offers a cerebrospinal fluid liquid biopsy assay called CNSide/IN-CNSide, designed to detect circulating tumor cells in cerebrospinal fluid. This microfluidic CTC assay is used for disease surveillance in patients with leptomeningeal dissemination and central nervous system cancers, providing an alternative to conventional cytology when standard methods remain negative.

Product and service1 record
1CNSide / IN-CNSide Cerebrospinal Fluid Liquid Biopsy Assay
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of the Parsortix CTC isolation platform for liquid biopsy, including oncology applications. Closest direct peer to Biocept in microfluidic / immunogenomics-independent CTC capture for clinical diagnostics and pharma services.

TypeBroad incumbent
Description

Established molecular diagnostics company with Signatera (tumor-informed MRD) and growing oncology liquid biopsy footprint. Competes for the same oncologist budgets and payer coverage decisions as Biocept's CNSide.

TypeBroad incumbent
Description

Leading broad liquid biopsy platform with Guardant360 CDx, Guardant Reveal MRD, and ongoing CNS/leptomeningeal program extensions. A much larger incumbent whose multi-analyte panels compete for the same oncology liquid-biopsy spend.

TypeEmerging player
Description

Emerging oncology molecular diagnostics company with NeXT Personal (tumor-informed MRD) and other liquid biopsy products. Comparable as a smaller, focused liquid biopsy oncology player pursuing MRD/recurrence monitoring.

TypeBroad incumbent
Description

Genomic diagnostics company with oncology/urology products and growing liquid biopsy franchise (Decipher, Afirma, Oncotype DX acquisition). Broad incumbent with comparable oncology molecular diagnostic positioning.

TypeBroad incumbent
Description

Major oncology diagnostics player with Cologuard and Oncotype products, expanding into liquid biopsy for multi-cancer and MRD applications. Competes for screening and recurrence-monitoring oncology testing share.

TypeDirect peer
Description

Manufacturer of the CELLSEARCH system, the established circulating tumor cell (CTC) enumeration platform. Direct technological competitor to Biocept's microfluidic CTC capture platform, addressing similar oncology liquid-biopsy use cases across metastatic disease monitoring.

TypeEmerging player
Description

Blood-based immune-repertoire diagnostics company with oncology and minimal residual disease applications. Related through blood-based oncology recurrence monitoring but uses a distinct (immunosequencing) technology.

TypeBroad incumbent
Description

Specialty oncology reference laboratory offering liquid biopsy, NGS tumor profiling, and clinical trial services. Broad incumbent with overlapping oncology diagnostic services and clinical trial support orientation.

TypeDirect peer
Description

CTC-focused liquid biopsy company offering single-cell CTC characterization for oncology therapy selection and monitoring. Direct competitor with overlapping CTC platform and oncology diagnostic positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocept

Molecular Cancer Diagnosticsbiocept.com

Biocept is a San Diego-based clinical diagnostics company that develops microfluidic circulating tumor cell liquid biopsy assays, primarily serving neuro-oncologists with its CNSide cerebrospinal fluid assay for CNS cancer and leptomeningeal disease monitoring.

What Biocept does

Biocept is a San Diego-based clinical diagnostics company founded in 1993 and publicly traded on NASDAQ under ticker BIOC. The company developed a proprietary circulating tumor cell (CTC) detection platform built on a microfluidic chip-based cell separation technology, which it applies to liquid biopsy testing in oncology. Its lead commercial product is CNSide (also referenced as IN/CNSide), a cerebrospinal fluid (CSF) liquid biopsy assay designed to detect CTCs expressing the neuroendocrine marker synaptophysin in patients with leptomeningeal disease and central nervous system (CNS) cancers — a positioning differentiated from most liquid biopsy peers that focus on blood-based analysis. The assay is being evaluated in the FORESEE clinical trial for clinical validation.

Biocept operates as a clinical laboratory offering laboratory-developed tests (LDTs) to practicing oncologists and neuro-oncologists, generating revenue through test reimbursement rather than a direct-to-consumer or kit-based model. Its customer base is concentrated among neuro-oncology practices and academic medical centers managing patients with CNS metastases or leptomeningeal carcinomatosis. Pricing, payer mix, and reimbursement structure are not publicly disclosed in available sources. The company has raised approximately $48 million cumulatively across equity rounds from 2002 through 2023, with the most recent disclosed raise of $5 million in May 2023.

Operationally, Biocept runs a lean organization of 51-100 employees under a leadership team including CEO Antonino Morales, Chairman Samuel D. Riccitelli, COO Philippe Marchand, CMO Michael Dugan, CSO Lyle Arnold, and General Counsel Darrell Taylor. A material operational concern is that the company's website returned a DNS resolution error as of July 2026, which is consistent with severe financial distress, business interruption, or potential wind-down — a critical diligence flag for any investor or counterparty evaluating the company.

Biocept firmographics

Firmographics
Name
Biocept
Legal name
Biocept Inc.
Website
https://biocept.com
Company type
Public
Founded year
1993
Operating status
Operating
Headcount range
11–50 employees
Short description
Biocept is a San Diego-based clinical diagnostics company that develops microfluidic circulating tumor cell liquid biopsy assays, primarily serving neuro-oncologists with its CNSide cerebrospinal fluid assay for CNS cancer and leptomeningeal disease monitoring.
Ownership category
akta.pro rank

Biocept industry classification

Industry
Product category
Molecular Cancer Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Liquid biopsy diagnostics
  • Circulating tumor cells
  • Cancer diagnostic assays
  • Microfluidic chip platform
  • Cerebrospinal fluid assay

Where Biocept is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Biocept business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Biocept product offering

Product offering

Core offering

Biocept develops and commercializes cerebrospinal fluid liquid biopsy assays — principally the CNSide/IN-CNSide assay — that detect circulating tumor cells (CTCs) expressing synaptophysin. These microfluidic chip-based assays are used by clinicians to monitor patients with leptomeningeal disease and central nervous system cancers when conventional cytology fails to identify malignant cells.

Product overview

Biocept offers a cerebrospinal fluid liquid biopsy assay called CNSide/IN-CNSide, designed to detect circulating tumor cells in cerebrospinal fluid. This microfluidic CTC assay is used for disease surveillance in patients with leptomeningeal dissemination and central nervous system cancers, providing an alternative to conventional cytology when standard methods remain negative.

Differentiator

Problem solved

Functional benefit

Products and services

  • CNSide / IN-CNSide Cerebrospinal Fluid Liquid Biopsy Assay

Quantifiable outcome

  • Detected CTCs expressing synaptophysin in CSF at seven time points over eight months while conventional cytology remained negative throughout monitoring period

Companies that use Biocept

Customer profile

Ideal customer profiles1 record

Biocept technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Biocept partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

Biocept competitors and assessment

Company assessment

Direct peers

  • ANGLE plc: Developer of the Parsortix CTC isolation platform for liquid biopsy, including oncology applications. Closest direct peer to Biocept in microfluidic / immunogenomics-independent CTC capture for clinical diagnostics and pharma services.
  • Menarini Silicon Biosystems: Manufacturer of the CELLSEARCH system, the established circulating tumor cell (CTC) enumeration platform. Direct technological competitor to Biocept's microfluidic CTC capture platform, addressing similar oncology liquid-biopsy use cases across metastatic disease monitoring.
  • Epic Sciences: CTC-focused liquid biopsy company offering single-cell CTC characterization for oncology therapy selection and monitoring. Direct competitor with overlapping CTC platform and oncology diagnostic positioning.

Broad incumbents

  • Natera: Established molecular diagnostics company with Signatera (tumor-informed MRD) and growing oncology liquid biopsy footprint. Competes for the same oncologist budgets and payer coverage decisions as Biocept's CNSide.
  • Guardant Health: Leading broad liquid biopsy platform with Guardant360 CDx, Guardant Reveal MRD, and ongoing CNS/leptomeningeal program extensions. A much larger incumbent whose multi-analyte panels compete for the same oncology liquid-biopsy spend.
  • Veracyte: Genomic diagnostics company with oncology/urology products and growing liquid biopsy franchise (Decipher, Afirma, Oncotype DX acquisition). Broad incumbent with comparable oncology molecular diagnostic positioning.
  • Exact Sciences: Major oncology diagnostics player with Cologuard and Oncotype products, expanding into liquid biopsy for multi-cancer and MRD applications. Competes for screening and recurrence-monitoring oncology testing share.
  • NeoGenomics: Specialty oncology reference laboratory offering liquid biopsy, NGS tumor profiling, and clinical trial services. Broad incumbent with overlapping oncology diagnostic services and clinical trial support orientation.

Emerging players

  • Personalis: Emerging oncology molecular diagnostics company with NeXT Personal (tumor-informed MRD) and other liquid biopsy products. Comparable as a smaller, focused liquid biopsy oncology player pursuing MRD/recurrence monitoring.
  • Adaptive Biotechnologies: Blood-based immune-repertoire diagnostics company with oncology and minimal residual disease applications. Related through blood-based oncology recurrence monitoring but uses a distinct (immunosequencing) technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Biocept social profiles

Digital presence

Biocept financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocept leadership team

Management profile

Number of profiles

Profiles6 records

Biocept funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocept M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocept

What does Biocept do?

Biocept develops and commercializes cerebrospinal fluid liquid biopsy assays — principally the CNSide/IN-CNSide assay — that detect circulating tumor cells (CTCs) expressing synaptophysin. These microfluidic chip-based assays are used by clinicians to monitor patients with leptomeningeal disease and central nervous system cancers when conventional cytology fails to identify malignant cells.

Is Biocept a public or private company?

Biocept is a public company. It is classified as public and is currently operating.

When was Biocept founded?

Biocept was founded in 1993. It employs 11 to 50 people.

Where is Biocept based?

Biocept is headquartered in San Diego, United States, in the North America region.

Who are Biocept's main competitors?

Direct peers on record are ANGLE plc, Menarini Silicon Biosystems and Epic Sciences. Broad incumbents are Natera, Guardant Health, Veracyte, Exact Sciences and NeoGenomics. Emerging players are Personalis and Adaptive Biotechnologies.

Does Biocept have an API?

No public API is recorded for Biocept.

What industry is Biocept in?

Biocept's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesCirculating Tumor Cells Market Size, Share, Trends & Growth Forecast 2035 – PR TimesA market report by Wise Guys Report projects the Circulating Tumor Cells (CTC) market to grow from USD 6.67 billion in 2025 to USD 12.5 billion by 2035, driven by rising cancer incidence and the adoption of liquid biopsy technologies. The analysis highlights key growth drivers such as personalized medicine and technological advancements, while noting challenges including isolation difficulties and high costs. Major industry players like Thermo Fisher Scientific, Biocept, and Johnson & Johnson are identified as active contributors to this expanding sector.ReviewedMonitoring the Response of a Pineal Parenchymal Tumor of Intermediate Differentiation With Cerebrospinal Fluid Dissemination Using a Circulating Tumor Cell AssayThis case report describes a 27-year-old woman with pineal parenchymal tumor of intermediate differentiation (PPTID) who developed leptomeningeal disease and was monitored using the Biocept IN/CNSide cerebrospinal fluid liquid biopsy assay at seven time points over eight months alongside standard therapies. The assay detected circulating tumor cells expressing synaptophysin in the CSF when conventional cytology remained negative throughout, demonstrating its potential to improve disease surveillance in patients with leptomeningeal dissemination. The authors conclude that while investigational, this microfluidic CTC assay may serve as a supplementary monitoring tool for PPTID patients with leptomeningeal disease.BenzingaWhy Is Liquid Biopsy Firm Biocept Stock Trading Lower Today?Biocept Inc filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware, with President and CEO Antonino Morales and the entire board of directors resigning on the same day. The company had been exploring strategic alternatives since January, engaged EF Hutton as financial advisor, and implemented a restructuring plan cutting staff by approximately 35%, as Q2 revenue collapsed to $589,000 from $5.8 million a year ago due to sharply lower COVID-19 testing volume. Biocept's stock closed down 46.1% at $0.55 following the bankruptcy filing.BenzingaWhy Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?Biocept Inc signed a non-exclusive licensing agreement for its CNSide cerebrospinal fluid tumor cell enumeration platform with Plus Therapeutics Inc, expanding a prior laboratory services agreement first announced in June 2022. Plus Therapeutics will pay Biocept $150,000 upfront in stock, $6,000 per CSF analysis performed before technology transfer, and $300,000 plus sliding scale fees starting at $2,800 per test after transfer completion, with an optional exclusivity clause available for an additional $1,000,000. Plus Therapeutics is currently using CNSide in a clinical trial evaluating its targeted radiotherapeutic for treating patients with carcinomas or melanomas exhibiting suspected leptomeningeal metastases.Business Wire BlogBiocept Announces Pricing of $5.0 Million Underwritten Public OfferingBiocept, Inc. has priced an underwritten public offering of 1,176,470 shares and accompanying warrants at $4.25 per share, raising approximately $5.0 million in gross proceeds. The company intends to utilize the net proceeds to advance its FORESEE trial for CNSide, as well as for working capital and general corporate purposes. The transaction is expected to close on May 26, 2023, subject to customary closing conditions.BioSpaceBiocept Announces One-for-Thirty Reverse Stock SplitBiocept announced a 1-for-30 reverse stock split effective May 16, 2023, with trading resuming May 17 under the same symbol. Each 30 pre-split shares combined into one, and no fractional shares were issued; record holders received cash in lieu of fractional shares.BioSpaceBiocept Appoints Financial Executive Quyen Dao-Haddock to its Board of DirectorsBiocept appointed Quyen Dao-Haddock to its board of directors, effective immediately, increasing membership to eight. She will serve on the Audit Committee, bringing over 20 years of financial and accounting experience. The company expects her to support its efforts to establish CNSide as standard-of-care.BioSpaceBiocept to Hold Business Strategy Conference Call TodayBiocept will hold a conference call on June 7, 2022, at 4:00 p.m. Eastern to discuss its re-focused business strategy. The call will be accessible via dial-in and webcast, with a replay available for 48 hours. The company also offers RT-PCR COVID-19 testing.PR NewswireGlobal Liquid Biopsy Markets Report 2022-2027 Featuring Thermo Fisher Scientific, Guardant Health, EXACT Sciences Corp, Illumina, Bio - Rad Laboratories, Biocept, NeoGenomics, & Qiagen NVResearch and Markets published a comprehensive market report on the global liquid biopsy industry, projecting the market to reach US$ 8.1 billion by 2027, growing at an 18% CAGR from the 2021 baseline of US$ 3 billion. The report identifies key growth drivers including rising cancer prevalence, advancements in next-generation sequencing, increased patient preference for minimally invasive procedures, and expanding healthcare expenditure in developing countries such as China and India. COVID-19 initially constrained market growth by disrupting cancer screening programs and diagnostic supply chains, though the sector is expected to recover as healthcare systems normalize.BioSpaceBiocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance OfficerBiocept appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer, reporting to CEO Michael Nall. Taylor brings over 30 years of healthcare experience, including 20 years as a healthcare attorney and prior role as Chief Compliance Officer for Precision Diagnostics. He will support Biocept's oncology business and COVID-19 testing program.